Patents Examined by Paul Zarek
  • Patent number: 9549897
    Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the hormone estradiol, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: January 24, 2017
    Assignee: PHARMACEUTICAL PRODUCTIONS, INC.
    Inventor: John A. McCarty
  • Patent number: 9487515
    Abstract: Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: November 8, 2016
    Assignee: Plexxikon Inc.
    Inventors: Jiazhong Zhang, Prabha N. Ibrahim, Ryan Bremer
  • Patent number: 9447027
    Abstract: This document relates to compounds useful for treating cardiac arrhythmias, for example, long QT syndrome. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: September 20, 2016
    Assignee: The General Hospital Corporation
    Inventors: David J. Milan, David S. Peal
  • Patent number: 9447006
    Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: September 20, 2016
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Guy M. Miller, Sidney M. Hecht
  • Patent number: 9439938
    Abstract: The present invention relates to the use of avocado peels in order to obtain avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols, said avocado peels accounting for 5 to 50% by weight relative to the total weight of avocado used. The invention also relates to a method for obtaining avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols from at least avocado peels, said avocado peels accounting for 5 to 50% by weight relative to the total weight of avocado used. The invention also relates to an avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols, obtainable by this method. Lastly, the invention relates to an avocado unsaponifiable enriched in saturated aliphatic hydrocarbons and in sterols, for use as a drug, advantageously in the in the prevention and/or treatment of conjunctive tissue disorders such as arthrosis, articular pathologies such as rheumatism, or periodontal diseases such as gingivitis or periodontitis.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: September 13, 2016
    Assignee: LABORATOIRES EXPANSCIENCE
    Inventors: Philippe Msika, Jacques Legrand, Sebastien Garnier
  • Patent number: 9433610
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: September 6, 2016
    Assignees: Massachusetts Eye & Ear Infirmary, The Brigham and Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Patent number: 9427471
    Abstract: The present disclosure relates to the use of an agent that enhances transdermal delivery of a PDE-5 inhibitor. More particularly, the present disclosure provides improved method and composition that promotes transdermal delivery of a PDE-5 inhibitor for the treatment of the PDE-5 mediated conditions and/or diseases.
    Type: Grant
    Filed: December 26, 2011
    Date of Patent: August 30, 2016
    Assignee: Tritech Biopharmaceuticals Co., Ltd.
    Inventors: Yee-Chien Liu, Pei-Ling Wu
  • Patent number: 9427009
    Abstract: The invention relates to an edible product containing a decontaminant. Particularly, the invention relates to an edible product, for instance, a food-like product, containing an effective amount of activated charcoal to mitigate, substantially reduce or cause the cessation of at least one adverse effect associated with the ingestion of a toxic substance. The invention also relates to methods for manufacturing such a decontaminant edible product and uses thereof.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 30, 2016
    Assignee: DENOVO INC.
    Inventor: Michael A. Stang
  • Patent number: 9420808
    Abstract: Compositions and methods for increasing lean muscle mass and/or reducing fat gain in growing animals by feeding the animals a composition having a total lysine to metabolizable energy ratio of from about 2.5 to about 6 g/Mcal and comprising (a) arginine in a total arginine to total lysine ratio of from about 1.1 to about 1.6; (b) isoleucine in a total isoleucine to total lysine ratio of from about 0.8 to about 1.3; (c) leucine in a total leucine to total lysine ratio of from about 1.8 to about 3.0; (d) valine in a total valine to total lysine ratio of from about 0.8 to about 1.4; and (e) methionine and cystine in a total methionine plus cystine to total lysine ratio of from about 0.8 to about 1.7.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: August 23, 2016
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Ryan Michael Yamka, Kim Gene Friesen, Steven Curtis Zicker
  • Patent number: 9408825
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: August 9, 2016
    Assignees: BRIGHAM YOUNG UNIVERSITY, COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Robert J. Handa
  • Patent number: 9402852
    Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: August 2, 2016
    Assignees: Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
  • Patent number: 9393216
    Abstract: Described are drug delivery systems incorporating electrospun fibers that comprise and deliver physicochemically diverse drug compounds. Such fibers provide significant advantages in drug agent release, such as adaptability for solid dosage delivery to mucosal tissues. This is in addition to allowing for controlled drug release. Systems and methods for large-scale electrospinning productivity are described, including novel microarchitectures allowing for variable pharmacokinetics in drug release.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: July 19, 2016
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Kim A. Woodrow, Cameron Ball, Anna Blakney, Emily Krogstad, Huarong Nie
  • Patent number: 9388175
    Abstract: This invention concerns the use of a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C1-6alkyl, Het1, HO—C1-6alkyl-, cyano-C1-6alkyl-, amino-C(?O)—C1-6alkyl-, formylamino-C1-6alkyl-, C1-6alkyl-C(?O)—NH—C1-6alkyl-, mono- or di(C1-6alkyl)amino-C(?O)—C1-6alkyl-, phenyl-C1-6alkyl-, or Het4-C1-6alkyl-; Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C1-6alkyl, C1-6alkyl-O—, C1-6alkylthio, Ar or polyhaloC1-6alkyl; L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C1-6alkyl
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: July 12, 2016
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Johannes Wilhelmus John F. Thuring, Gregor James MacDonald, Christopher James Grantham, Theodorus Dinklo, Anne Simone Josephine Lesage
  • Patent number: 9382204
    Abstract: The present invention provides STAT3 inhibitors which preferentially suppress proliferation of cancer over non-cancer cells and inhibit migration and invasion of malignant cells. The inhibitors of the present invention selectively inhibit STAT3 binding to DNA without affecting the activation and dimerization of STAT3. Furthermore, the inhibitors of the present invention inhibit expression of STAT3 downstream target genes and STAT3 binding to chromatin in situ.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: July 5, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Jian-Ting Zhang
  • Patent number: 9376416
    Abstract: Provided are: a composition containing scirpusin B, which is a composition derived from a natural material and contains scirpusin B at a high content; and a process for producing the composition containing scirpusin B.A composition containing scirpusin B is produced by the extraction from a passion fruit seed. In the extraction of scirpusin B, the passion fruit seed is crushed, and subsequently at least one solvent selected from a hydrous alcohol solvent and a hydrous ketone solvent is added to the crushed product to thereby extract scirpusin B into the solvent.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: June 28, 2016
    Assignee: MORINAGA & CO., LTD.
    Inventors: Shoko Sano, Kenkichi Sugiyama
  • Patent number: 9375433
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: June 28, 2016
    Assignee: Tangent Reprofiling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Patent number: 9375403
    Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 28, 2016
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: E. Itzhak Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
  • Patent number: 9375430
    Abstract: Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 28, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Margery Connelly, Christopher M. Flores, Mark J. Macielag
  • Patent number: 9370505
    Abstract: The invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as therapeutic agents.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: June 21, 2016
    Assignee: Mereo BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur
  • Patent number: 9364452
    Abstract: There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from Ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: June 14, 2016
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il Chan Kim, Se Jong Han, Hyoung Seok Lee, Hari Datta Bhattarai, Su-Geun Yang, Lee Don Hang